Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
CHEK logo CHEK
Upturn stock ratingUpturn stock rating
CHEK logo

Check Cap Ltd (CHEK)

Upturn stock ratingUpturn stock rating
$0.64
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: CHEK (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $7

1 Year Target Price $7

Analysts Price Target For last 52 week
$7 Target price
52w Low $0.56
Current$0.64
52w High $3.04

Analysis of Past Performance

Type Stock
Historic Profit -6.2%
Avg. Invested days 53
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 2.0
Stock Returns Performance Upturn Returns Performance 1.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 3.80M USD
Price to earnings Ratio -
1Y Target Price 7
Price to earnings Ratio -
1Y Target Price 7
Volume (30-day avg) 1
Beta 0.21
52 Weeks Range 0.56 - 3.04
Updated Date 08/29/2025
52 Weeks Range 0.56 - 3.04
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -2.14

Earnings Date

Report Date 2025-08-28
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -

Management Effectiveness

Return on Assets (TTM) -33.21%
Return on Equity (TTM) -53.03%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -20990855
Price to Sales(TTM) -
Enterprise Value -20990855
Price to Sales(TTM) -
Enterprise Value to Revenue -
Enterprise Value to EBITDA 0.74
Shares Outstanding 5851040
Shares Floating 4745020
Shares Outstanding 5851040
Shares Floating 4745020
Percent Insiders 18.91
Percent Institutions 2.08

ai summary icon Upturn AI SWOT

Check Cap Ltd

stock logo

Company Overview

overview logo History and Background

Check Cap Ltd is an Israeli-based company founded in 2005. It is focused on developing and commercializing C-Scan, an ingestible capsule for colon cancer screening.

business area logo Core Business Areas

  • C-Scan Development: Development and enhancement of the C-Scan system for colon cancer screening.
  • Commercialization: Efforts to market and sell the C-Scan system globally, primarily in areas where colon cancer screening is low.
  • Clinical Trials: Conducting clinical trials to validate the safety and efficacy of C-Scan.

leadership logo Leadership and Structure

Check Cap Ltd. typically has a CEO, CFO, and a board of directors. The organizational structure is likely functional, with departments for R&D, marketing, and operations.

Top Products and Market Share

overview logo Key Offerings

  • C-Scan System: The C-Scan system is Check Cap's primary offering. It consists of an ingestible capsule, recording device, and analysis software used for colon cancer screening. Market share is low due to the product being in development phase but potential total addressable market is the population that requires colon cancer screening. Main competitors are colonoscopies and fecal occult blood tests (FOBT).

Market Dynamics

industry overview logo Industry Overview

The colon cancer screening market is large and growing, driven by an aging population and increasing awareness of early detection. Traditional screening methods include colonoscopies and stool-based tests.

Positioning

Check Cap aims to disrupt the colon cancer screening market with its non-invasive, patient-friendly C-Scan technology. It competes with existing screening methods like colonoscopies and FOBT.

Total Addressable Market (TAM)

The TAM for colon cancer screening is estimated to be in the billions of dollars globally. Check Cap's positioning focuses on individuals unwilling or unable to undergo traditional colonoscopies.

Upturn SWOT Analysis

Strengths

  • Non-invasive screening method
  • Patient-friendly alternative to colonoscopies
  • Proprietary technology

Weaknesses

  • Limited clinical data
  • Regulatory hurdles for approval
  • Commercialization challenges
  • High cash burn rate and continued losses.

Opportunities

  • Partnerships with healthcare providers
  • Expansion into new markets
  • Development of additional applications for the C-Scan technology
  • Increased awareness of colon cancer screening importance

Threats

  • Competition from established screening methods
  • Reimbursement challenges from insurance companies
  • Technological advancements by competitors
  • Regulatory changes and delays

Competitors and Market Share

competitor logo Key Competitors

  • Exact Sciences (EXAS)
  • Guardant Health (GH)
  • Freenome (Private)

Competitive Landscape

Check Cap's C-Scan offers a non-invasive alternative, however, competitors such as Exact Sciences hold the majority market share with their stool-based screening tests.

Growth Trajectory and Initiatives

Historical Growth: Historical growth has been limited, primarily focused on R&D and clinical trial progress.

Future Projections: Future growth is contingent on successful commercialization of C-Scan and achieving regulatory approvals.

Recent Initiatives: Recent initiatives typically include conducting clinical trials, seeking regulatory approvals, and establishing partnerships with healthcare providers.

Summary

Check Cap Ltd is a development-stage company focused on colon cancer screening. Its innovative C-Scan technology aims to offer a non-invasive alternative to traditional methods. However, it faces significant challenges in clinical validation, regulatory approval, and commercialization, and competes against established players. The company's success depends on its ability to successfully commercialize C-Scan and capture market share. The company needs to focus on building a strong network with healthcare providers.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Company SEC Filings (10-K, 10-Q)
  • Company Investor Relations
  • Analyst Reports (where available)
  • Industry Publications

Disclaimers:

This analysis is for informational purposes only and does not constitute investment advice. Financial data is based on publicly available information and may not be completely up-to-date. Market share estimates are approximate and based on available data.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Check Cap Ltd

Exchange NASDAQ
Headquaters -
IPO Launch date 2015-02-19
CEO -
Sector Healthcare
Industry Diagnostics & Research
Full time employees -
Full time employees -

Check-Cap Ltd., a clinical stage medical diagnostics company, engages in the development of a capsule-based screening technology that utilizes ultra-low-dose X-rays to scan the inner lining of the colon for precancerous polyps, and other structural abnormalities in Israel. Its C-Scan system consists of C-Scan Cap, an X-ray scanning capsule for detection of suspected polyps; C-Scan Track, a disposable system attached to the patient's back through biocompatible adhesive skin patches; and C-Scan View software, a client/server-based application that enables procedure data download from the C-Scan Track, data analysis, and report generation. The company was incorporated in 2004 and is based in Isfiya, Israel.